Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics, Inc. - Common Stock
(NQ:
DYN
)
23.99
-0.31 (-1.28%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,456,239
Open
23.91
Bid (Size)
20.78 (1)
Ask (Size)
26.25 (1)
Prev. Close
24.30
Today's Range
23.65 - 24.90
52wk Range
12.06 - 47.45
Shares Outstanding
58,310,703
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
November 07, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+83.69%
+83.69%
1 Month
-19.20%
-19.20%
3 Month
-30.72%
-30.72%
6 Month
-32.67%
-32.67%
1 Year
+89.64%
+89.64%
More News
Read More
Looking Into Dyne Therapeutics's Recent Short Interest
October 22, 2024
Via
Benzinga
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
October 09, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Peering Into Dyne Therapeutics's Recent Short Interest
September 30, 2024
Via
Benzinga
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm
September 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
September 16, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf of Dyne Stockholders and Encourages Investors to Contact the Firm
September 10, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)
September 09, 2024
From
Kirby McInerney LLP
Via
Business Wire
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
September 08, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
September 04, 2024
From
The Schall Law Firm
Via
Business Wire
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
September 03, 2024
Via
Benzinga
Exposures
Fossil Fuels
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
September 03, 2024
Via
Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
September 03, 2024
Via
Investor's Business Daily
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
Nasdaq Dips Over 2%; US Construction Spending Falls In July
September 03, 2024
Via
Benzinga
Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates
September 03, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 03, 2024
Via
Benzinga
Dyne Therapeutics Announces Key Leadership Appointments
September 03, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
September 03, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?
August 21, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?
August 13, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024
August 12, 2024
Via
InvestorPlace
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.